Elevation of B cell-activating factor belonging to the tumour necrosis family family (BAFF) in haemophilia A patients with inhibitor

Tomohiro Takeda; Yoshihiko Sakurai; Kohei Tatsumi; Junko Kato; Shogo Kasuda; Akira Yoshioka; Midori Shima

doi:10.1160/TH08-08-0543

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(02): 408-410
DOI: 10.1160/TH08-08-0543

Letters to the Editor

Schattauer GmbH

Elevation of B cell-activating factor belonging to the tumour necrosis family family (BAFF) in haemophilia A patients with inhibitor

Tomohiro Takeda

¹Department of Pediatrics, Nara Medical University School of Medicine, Kashihara, Japan

²Clinical Laboratory, Uda General Hospital, Uda, Japan

,

Yoshihiko Sakurai

¹Department of Pediatrics, Nara Medical University School of Medicine, Kashihara, Japan

,

Kohei Tatsumi

¹Department of Pediatrics, Nara Medical University School of Medicine, Kashihara, Japan

,

Junko Kato

¹Department of Pediatrics, Nara Medical University School of Medicine, Kashihara, Japan

,

Shogo Kasuda

¹Department of Pediatrics, Nara Medical University School of Medicine, Kashihara, Japan

,

Akira Yoshioka

¹Department of Pediatrics, Nara Medical University School of Medicine, Kashihara, Japan

,

Midori Shima

¹Department of Pediatrics, Nara Medical University School of Medicine, Kashihara, Japan

› Author Affiliations

Abstract

Full Text

References

References
1 Qian J, Borovok M, Bi L. et al. Inhibitor antibody development and T cell response to human factor VIII in murine haemophilia A. Thromb Haemost 1999; 81: 240-244.
2 Lavigne-Lissalde G, Schved JF, Granier C. et al. Anti-factor VIII antibodies: a 2005 update. Thromb Haemost 2005; 94: 760-769.
3 Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2: 465-475.
4 Dillon SR, Gross JA, Ansell SM. et al. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235-246.
5 Bischof D, Elsawa SF, Mantchev G. et al. Selective activation of TACI by syndecan-2. Blood 2006; 107: 3235-3242.
6 Toubi E, Gordon S, Kessel A. et al. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with auto-immunity. J Autoimmun 2006; 27: 134-139.
7 Lesley R, Xu Y, Kalled SL. et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20: 441-453.
8 Thien M, Phan TG, Gardam S. et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785-798.
9 Bosello S, Pers JO, Rochas C. et al. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy. Int J Immunopathol Pharmacol 2007; 20: 1-8.
10 Groom J, Kalled SL, Cutler AH. et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest 2002; 109: 59-68.
11 Migita K, Abiru S, Maeda Y. et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 2007; 68: 586-591.
12 Hausl C, Maier E, Schwarz HP. et al. Long-term persistence of anti-factor VIII antibody-secreting cells in haemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 840-845.
13 Castigli E, Scott S, Dedeoglu F. et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004; 101: 3903-3908.
14 Mathias M, Khair K, Hann I. et al. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-368.
15 Carcao M, St Louis J, Poon MC. et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006; 12: 7-18.
16 Collins PW. Treatment of acquired haemophilia A. J Thromb Haemost 2007; 5: 893-900.
17 Cohen SB. Updates from B cell trials: efficacy. J Rheumatol (Suppl) 2006; 77: 12-17.